Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of oma102 in the treatment of female pattern hair loss

Conditions: Female Pattern Baldness

Summary: the goal of this clinical trial is to evaluate the efficacy and safety of oma102 1 mg and oma102 2 mg versus placebo in the treatment of female pattern hair loss.


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * age greater than 18 and equal or under 50 years; * confirmed diagnosis of female pattern hair loss, grade ii to iv in sinclair scale; * participants that are disposed to maintain the same hair color, style, approximate hair length throughout the clinical study. exclusion criteria: * any clinical or physical finding interpreted by the investigator as a risk to subject participation in the clinical study * history of alcohol or illicit drugs abuse in the last year; * pregnant or breastfeeding women, who are planning to become pregnant or participants who have childbearing potential and are not using any reliable contraceptive method; * allergy or sensibility to any knowing components of the formula; * diagnosis of arterial hypertension; * history of vasovagal syncope; * baseline systolic blood pressure lower than 90 mmhg and/or diastolic lower than 60 mmhg; * diagnosis of orthostatic hypotension (reduction of systolic blood pressure equal or superior to 20 mmhg and/or diastolic equal or superior to 10 mmhg after 3 minutes in orthostatic position); * body mass index (bmi) \> 30 kg/m²; * subjects that initiated any kind of continue use medication, including contraceptives with systemic effect, until 3 months previously the inclusion in the clinical study; * history of cardiovascular, liver and renal diseases; * history of hypothyroidism, hyperthyroidism or pheochromocytoma; * signs or symptoms of cardiopathy or angina; * history of edema from any etiology; * participants who are using tricycle antidepressants, benzodiazepines, antipsychotics, anticholinergics, sulfonamide derivatives, beta-blockers, sympathomimetics, arginine, glucocorticoid or monoamine oxidase inhibitors; * use of inhibitor of 5-alpha reductase or androgenic blockers in the last 12 months; * dermatologic diseases of the scalp, except mild seborrheic dermatitis or diagnosis of any kind of alopecia other than female pattern hair loss; * history of surgical treatment for hair loss or presence of shaved scalp; * scalp microinfusion, microneedling or intradermotherapy in the last 3 years; * vaginal or cesarean deliveries 6 months before the inclusion in the study; * drastic modification of habitual diet, as food restrictions or hyperselectivity; * current cancer or history of cancer in the last 5 years; * participation in others research protocols in the last 12 months, unless the investigator judges that there may be a direct benefit to the participant.
efficiency study of aspirin to prevent the occurrence of prostate cancer

Conditions: Prostate Cancer

Summary: though the pathogenesis of prostate cancer (pca) is still obscure, it has been reported, by investigators previous studies and some other researches, that pca is often combined with tissue inflammation which is closely related to prostate specific antigen (psa) level. inflammation could play an important role in the process of occurrence and development of pca, however the mechanism is unknown. inflammatory cytokines could not only mediate inflammatory reactions, but also participate in the growth, proliferation, invasion and progression of tumor cells. it has been found that non-steroid anti-inflammatory drugs (nsaids), such as aspirin, can effectively prevent several inflammation related tumor, and coincidentally, pca is also closely associated with inflammation. moreover, latest researches demonstrated that hormone therapy could induce tissue inflammation in pca, in which a large quantity of immune b cells were attracted into the focal and then a lot of cytokines, such as ikk-β, nf-κb, were released. these cytokines could inhibit apoptosis and promote the growth of tumor cells, which might be a possible mechanism for long-term inflammatory infiltration inducing the occurrence of pca and the transformation to castration-resistant prostate cancer (crpc). based on these proofs, investigators presume it could be possibly an effective way to prevent the occurrence of pca and the transformation from androgen-dependent prostate cancer to crpc by means of long-term oral aspirin. in this study, investigators intend to explore the possible effect of anti-inflammatory therapy on the progress of transformations from inflammation to pca and from androgen-dependent prostate cancer to crpc. investigators plan to conduct both clinical trials in four groups, including the control group, the nsaids group, the antibiotics group and the nsaids+antibiotics group, and a basic experiment in vitro to assess the effectiveness of anti-inflammatory drugs and elucidate the specific molecular mechanism.


Eligibility criteria:
inclusion criteria: * prostate specific antigen(psa)\>10ng/ml * suspected of prostate cancer * prostate biopsy showed benign prostate hyperplasia with infiltrated with lymphocytes exclusion criteria: * serious complication:heart disease;respiratory disease;blood disease; * refused to join the trial * disease of hemorrhagic tendency

Keywords: aspirin
opaline : a study of morbidity and mortality at 2 years

Conditions: Pancreatic Neuroendocrine Tumor, Well Differentiated and Progressive

Summary: a descriptive, prospective (partly retrospective), multisite, observational study conducted in france in adult patients treated for a well differentiated, unresectable or metastatic, pancreatic neuroendocrine tumor with disease progression.

prospective and retrospective analyses will be performed using sas® software

Eligibility criteria:
inclusion criteria: * patients over 18 years of age; * patients treated with a targeted therapy (sunitinib, everolimus) or with other treatments (interferon, or metabolic radiotherapy, or chemotherapy or somatostatin analog)\* for: \*patients whose treatment line (targeted therapy or other treatment) is initiated as a 1st, 2nd, 3rd or 4th line of therapy at the time of inclusion (incident patients) or patients receiving their 1st, 2nd, 3rd or 4th line of therapy provided that treatment was initiated in the site in which the patient is enrolled in the study (prevalent patients); a change of line is defined as a change in molecule or combination. * a histologically confirmed unresectable or metastatic pancreatic neuroendocrine tumor; * well-differentiated; * progressive prior to initiation of treatment in the investigator's judgment (clinical or radiological progression); * patients who have been informed of the conditions of the study and who have signed the informed consent. exclusion criteria: * patients with a diagnosis of poorly differentiated neuroendocrine carcinoma or an adenoneuroendocrine carcinoma. * patients receiving targeted therapy (everolimus or sunitinib) already received in a previous line of treatment (rechallenged patient). * patients refusing to give consent. * patients receiving a fifth line or subsequent line of systemic treatment. * patients participating in a clinical trial in a treatment arm not validated by the ma and the tncd according to the version dated december 2013. * patients randomized to the placebo arm of a placebo-controlled trial or to a double-blind trial.
incidence and severity of postoperative sore throat and intubation response by using different devices for endotracheal intubation

Conditions: Pharyngitis; Endotracheal Intubation; Pain

Summary: postoperative sore throat (post) is a common problem following the use of endotracheal intubation during general anaesthesia. it leads to dissatisfaction and discomfort after surgery and can delay a patient's return to normal routine activities. post has been rated by patients as the eighth most adverse effect in the postoperative period. the incidence of sore throat after endotracheal intubation varies from 14.4-90%. laryngoscopy and tracheal intubation also leads to hemodynamic stress response. the response can be deleterious in patient with or without cardiac disease. it is related to the degree of manipulation of the airway during endotracheal intubation and has been studied during intubation for some equipment used for endotracheal intubation


Eligibility criteria:
inclusion criteria: * after signing of the informed consent, * asa physical status i and ii * mallampati class 1\& 2, * bmi \< 35, * undergoing elective surgical procedures (not exceeding two hours in duration) requiring et intubation exclusion criteria: * patients undergoing day case, * bariatric, cardiac, nasal, oral or head \& neck surgeries, * requiring placement of throat pack or nasogastric/ orogastric tube, * patients assigned to rapid sequence induction, * hoarseness, * patients with anticipated difficult intubation, * history of recent upper respiratory tract infection, * history of difficult intubation * psychiatric disorders hindering proper evaluation, * use of steroids (oral or inhalational) or non-steroidal anti-inflammatory drugs within one week of surgery or previous surgery within last two weeks

Keywords: measurement
evaluate the use of ganciclovir gel 0.3% for the treatment of conjunctivitis caused by adenovirus

Conditions: Conjunctivitis; Adenovirus.

Summary: the purpose of this study is to study the use of ganciclovir gel 0.3% for treatment of conjunctivitis caused by adenovirus.

to evaluate the efficacy and tolerability of ganciclovir ophthalmic gel for the treatment of conjunctivitis comparing to placebo (ophthalmic gel). visual acuity test and slit lamp examination (biomicroscopy) will be performed at each visit to assess the signs/symptoms and the regression of the disease.

Eligibility criteria:
inclusion criteria: * patients with eye disease with a clinical diagnosis of adenovirus conjunctivitis. * patients of both gender aged over 18 years. * patients who are not pregnant or nursing. * patients able (legally and mentally) to understand and sign informed consent had been signed. exclusion criteria: * patients who are in the presence of corticosteroids, either by topical ocular, periocular, intraocular or systemic, for less than 30 days of enrollment and who can not make a drug suspension. * patients with serious systemic diseases like aids, cancer, etc., which in the opinion of the investigator, may put the patient at risk. * patient with a single eye or vision in one eye.

Keywords: conjunctivitis adenovirus.
abdominal sacral hysteropexy versus vaginal sacrospinous hysteropexy

Conditions: Pelvic Organ Prolapse

Summary: the aim of the current study is to compare abdominal sacral cervicopexy with vaginal sacrospinous cervicopexy in women with apical prolapse in terms of operative time, procedures safety and efficacy.

according to cochrane group trials , abdominal approaches centered on sacral colpopexy is associated with lower risk of awareness of prolapse, repeat surgery for prolapse and dyspareunia than a variety of vaginal interventions. however, these trials weren't statistically significant and have focused on the effects in terms of anatomy and lacked the effect on functional outcomes, the quality of life, perioperative complications and the operative duration. in this study, we hypothesize that prolonged operative duration will be associated with a greater risk of developing complications and so may guide us to a minimally invasive approach with better functional outcomes.

Eligibility criteria:
inclusion criteria: * in order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. symptomatic apical descent stage ii or more. 2. eligible for both surgical procedures 3. no uterine or cervical pathology. 4. able to consent to participate in the trial. exclusion criteria: 1. women with contraindication to any surgical procedures. 2. women with previous apical prolapse surgery. 3. one of the two surgical approaches is not feasible. 4. women with concomitant surgical procedures apart from correction of the prolapse. 5. women who prefer to have hysterectomy.
efficacy of lauric acid, a dietary fatty acid, in modifying the latent reservoir of hiv

Conditions: HIV Infections

Summary: dietary lauric acid supplementation could have a significant impact on the hiv reservoir in antiretroviral-treated patients by inducing hiv viral transcription in latently infected cells and preserving the hiv-specific immune response, without causing toxicity. design: pilot, randomized, placebo-controlled, patient-blind study. patients ≥18 years old with hiv-1 receiving stable art (no change in art for at least 6 months) and a serum hiv rna load of \ 300 cells/μl will be randomized 1:1:1 to dietary supplementation with placebo (controlled group) or lauric acid 1.5 g once daily (experimental group 1) or with lauric acid 3 g once daily (experimental group 2) for 24 consecutive weeks. primary objective: to assess the effect of dietary lauric acid supplementation, compared with placebo, on the reactivation of hiv transcription in latently infected cd4 t cells in hiv-infected patients on suppressive antiretroviral therapy.


Eligibility criteria:
inclusion criteria: * hiv-1 infected men or women ≥18 years old * not having interrupted current antiretroviral treatment at least 6 months before the screening visit. * acceptable stable art regimens prior to screening include 2 more nrtis: ini or nnrti or boosted pi. * documented prior evidence of at least 2 years prior to enrollment with a serum hiv rna load of \ 50 copies but \<200 is allowed). * plasma hiv-1 rna \<50 c/ml at screening visit. * cd4 t cell count \> 300 cells/µl at screening visit. a woman may be eligible to enroll and participate in the study if: * not pregnant, not of childbearing potential or physically unable to become pregnant * you are of childbearing potential with a negative pregnancy test at the screening visit and agree to use contraception to prevent pregnancy. exclusion criteria: * have suffered any significant acute illness in the last 8 weeks. * having been diagnosed in the past or present with an aids-defining illness * previous cd4 t cell count \<200 cells/μl. * having suffered an infection with hepatitis b or c * having any disease or condition that in the investigator's opinion is not appropriate for the patient's participation in the study.

Keywords: lauric acid hiv antiretroviral treatment
analysis of t cell and natural killer (nk) cell in relation to viral infections in pediatric stem cell transplant patients and donors

Conditions: Hematologic Malignancies

Summary: viral infections and reactivation during pediatric allogeneic hematopoietic stem cell transplantation (hsct) are a common occurrence and significantly contribute to post-transplant morbidity and mortality. the risk is high due to prolonged periods of immune deficiency while awaiting immune reconstitution post-transplant. current strategies to reduce complications from viral infections include prophylactic treatment, close monitoring for viral infections and prompt treatment at the first sign of symptoms or increasing viral load. however, the most definitive treatment for viral infections remains the host's cellular defenses. improved understanding of the immune systems response to viral infections may lead to better treatment strategies. this study is being done to explore the relationships between t-cells and nk cells (infection fighting cells) and viral infections or reactivations in young allogeneic stem cell transplant patients. the investigators will be looking at how these cells react and function in young patients receiving allogeneic stem cell transplantation, as well as in healthy stem cell donors.

primary objective: * to explore the expansion patterns of kir+cd56+ t-cells and fcrg-cd56+cd3- nk cells in response to viral infection and reactivation in pediatric allogeneic hematopoietic stem cell transplant (hsct) patients. secondary objectives: * to describe the phenotype of kir+cd56+ t-cells and fcrg-cd56+cd3- nk cells in pediatric allogeneic hsct patients and healthy donors. * to describe the specificity and functional capacity of kir+cd56+ t-cells against viral antigens in both pediatric allogeneic hsct patients and healthy donors. * to describe the functional capacity of fcrg-cd56+cd3- nk cells against cmv-infected cells in both pediatric allogeneic hsct patients and healthy donors.

Eligibility criteria:
inclusion criteria: * patients undergoing allogeneic hematopoietic stem cell transplant (hsct) for a hematologic malignancy or a donor for a patient undergoing allogeneic hematopoietic stem cell transplant for a hematologic malignancy. * for hsct patients: ages birth to 21 years old; for donors: any age. * for minors less than 18 years old, both parents must be available on st. jude campus to provide consent. one parent/legal guardian will be acceptable if one parent is deceased, incompetent, or when the one parent present has legal responsibility for the care and custody of the child. exclusion criteria: * patients undergoing allogeneic hematopoietic stem cell transplant for a disease other than a hematologic malignancy

Keywords: viral infection allogeneic stem cell transplant
safety, pharmacokinetics and pharmacodynamics of bez235 plus mek162 in selected advanced solid tumor patients

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Solid Tumor

Summary: this is an open label, dose finding, phase ib clinical trial to determine the maximum tolerated dose (mtd) and/or rp2d of the orally administered pi3k/mtor inhibitor bez235 in combination with the mek1/2 inhibitor mek162. this combination will be explored in patients with egfr mutant nsclc which has progressed on egfr inhibitors and triple negative breast cancer, as well as pancreatic cancer, colorectal cancer, malignant melanoma, nsclc, and other advanced solid tumors with kras, nras, and/or braf mutations. dose escalation will be guided by a bayesian logistic regression model with overdose control. at mtd or rp2d, two expansion arms will be opened in order to further assess safety and preliminary anti-tumor activity of the combination of bez235 and mek162. study drugs will be administered orally on a continuous schedule, mek162 bid and bez235 qd, a treatment cycle is defined as 28 days.


Eligibility criteria:
inclusion criteria: * histologically/cytologically confirmed, advanced non resectable solid tumors * measurable or non-measurable, but evaluable disease as determined by recist 1.0 exclusion criteria: * patients with primary cns tumor or cns tumor involvement * diabetes mellitus - unacceptable ocular/retinal conditions other protocol-defined inclusion/exclusion criteria may apply

Keywords: bez235, mek162 ras raf mutations, triple negative breast cancer pancreatic cancer, nsclc progressed on egfr tki pi3k/mtor inhibitor, mek inhibitor advanced and selected solid tumors
trial to evaluate radiotherapy with or without cbdca in elderly patients with non-small cell lung cancer (jcog0301)

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage iii nsclc.

the purpose of this study is to evaluate whether radiotherapy with carboplatin will result in longer survival than radiotherapy alone in elderly patients with unresectable stage iii nsclc.

Eligibility criteria:
inclusion criteria: * histologically and/or cytologically proven nsclc * unresectable disease * stage iiia except t3n1m0 and iiib which does not have disease extended to any contralateral hilar nodes, atelectasis of the entire lung or malignant pleural effusions * a required radiation field of less than one half of one lung * measurable disease * no previous chemotherapy or radiotherapy * age \>= 71 * unable to receive cisplatin-based combination chemotherapy * ecog performance status (ps) of 0-2 * adequate bone marrow, lung, hepatic, and renal function * written informed consent exclusion criteria: * active infection, diarrhea, ileus, uncontrolled diabetes, myocardial infarction within three months, or severe other comorbidity * synchronous cancer or metachronous (within 5 years) malignancy * interstitial pneumonia or active lung fibrosis on chest x-ray * severe chronic obstructive pulmonary disease, chronic bronchitis, or bronchial asthma * pleural or pericardial effusion * a history of severe hypersensitivity * mental disorder * judging of inappropriate condition for this study by physician

Keywords: non-small cell lung cancer elderly patients carboplatin chemoradiotherapy
intravitreal injections of ranibizumab with deferred laser grid laser photocoagulation for treatment of diabetic macular edema with visual impairment

Conditions: Diabetic Macular Edema

Summary: in the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. during follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.


Eligibility criteria:
inclusion criteria: * diabetes mellitus (1 or2) * decreased vision from diabetic macular edema (study eye best corrected visual acuity\<69 letters using e.t.d.r.s testing) * macular edema exclusion criteria: * history of severe cardiac disease * stroke within 12 months * intraocular inflammation
the necessity of an injection-meal-interval in patients with type 2 diabetes mellitus and therapy with human insulin

Conditions: Diabetes Mellitus Type 2

Summary: the purpose of the study is to demonstrate, that there is no difference in metabolic control in patients with type 2 diabetes mellitus and therapy with human insulin with or without injection-meal-interval.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * aged 40 - 80 years * therapy with human insulin exclusion criteria: * pregnancy * nutrition disorders * psychological disease * body mass index (bmi) less than 25 kg/m\^2 * hba1c greater than 9%

Keywords: injection to meal time human insulin